Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress ...Middle East

Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding benchmarks in the overall population and in DKK1 and PD-L1 subgroups Median Overall Survival is not mature with only 44% of patients deceased as...

Read More Details
Finally We wish PressBee provided you with enough information of ( Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress )

Also on site :

• RHOM star Larsa Pippen got ‘boob job, nose job, BBL and fillers’ to look like a ‘doll,’ top plastic surgeon claims
• Beloved '90s Actress, 53, Goes Makeup Free in Rare Summer Photos With Husband: 'Make the Time'
• ‘This is murder': Family remembers victims killed in Austin fire as 4th body recovered